Compare GDV & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GDV | IBRX |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.6B |
| IPO Year | N/A | N/A |
| Metric | GDV | IBRX |
|---|---|---|
| Price | $28.63 | $6.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $11.80 |
| AVG Volume (30 Days) | 186.0K | ★ 46.1M |
| Earning Date | 01-01-0001 | 03-02-2026 |
| Dividend Yield | ★ 5.81% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $82,555,000.00 |
| Revenue This Year | N/A | $680.06 |
| Revenue Next Year | N/A | $90.18 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1025.95 |
| 52 Week Low | $18.04 | $1.83 |
| 52 Week High | $23.00 | $8.28 |
| Indicator | GDV | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 64.54 | 75.41 |
| Support Level | $28.43 | $5.71 |
| Resistance Level | $28.50 | $8.28 |
| Average True Range (ATR) | 0.22 | 0.67 |
| MACD | -0.00 | 0.42 |
| Stochastic Oscillator | 88.31 | 67.10 |
Gabelli Dividend & Income Trust operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of total return on its assets with an emphasis on dividends and income. To achieve its objective, the fund may invest its assets in dividend-paying securities or other income-producing securities. The fund invests in various sectors, in which Financial Services, Food and Beverage, Health Care, Consumer Products, Electronics, and Computer Software & Services and others.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.